GH RESEARCH PLC DL-025 (F:1KA) — Market Cap & Net Worth
Market Cap & Net Worth: GH RESEARCH PLC DL-025 (1KA)
GH RESEARCH PLC DL-025 (F:1KA) has a market capitalization of $737.24 Million (€630.60 Million) as of August 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #10112 globally and #1226 in its home market, demonstrating a -2.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GH RESEARCH PLC DL-025's stock price €24.20 by its total outstanding shares 62029395 (62.03 Million).
GH RESEARCH PLC DL-025 Market Cap History: 2021 to 2026
GH RESEARCH PLC DL-025's market capitalization history from 2021 to 2026. Data shows growth from $1.36 Billion to $1.75 Billion (10.76% CAGR).
GH RESEARCH PLC DL-025 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GH RESEARCH PLC DL-025's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1KA by Market Capitalization
Companies near GH RESEARCH PLC DL-025 in the global market cap rankings as of August 1, 2026.
Key companies related to GH RESEARCH PLC DL-025 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
GH RESEARCH PLC DL-025 Historical Marketcap From 2021 to 2026
Between 2021 and today, GH RESEARCH PLC DL-025's market cap moved from $1.36 Billion to $ 1.75 Billion, with a yearly change of 10.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.75 Billion | +134.95% |
| 2025 | €746.94 Million | +59.69% |
| 2024 | €467.75 Million | +31.63% |
| 2023 | €355.34 Million | -38.75% |
| 2022 | €580.15 Million | -57.22% |
| 2021 | €1.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of GH RESEARCH PLC DL-025 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $737.24 Million USD |
| MoneyControl | $737.24 Million USD |
| MarketWatch | $737.24 Million USD |
| marketcap.company | $737.24 Million USD |
| Reuters | $737.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GH RESEARCH PLC DL-025
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorde… Read more